Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.33 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845502 | 0.93 | GRM1 (0.34) | GRM5GRM1AR | |
| SCHEMBL22845335 | 0.92 | GRM5 (0.36) | GRM5GRM1PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL22845309 | 0.91 | MAPK14 (0.34) | PRKAA2MAPK14NR3C1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22845431 | 0.90 | GRM5 (0.38) | GRM5GRM1PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL22845531 | 0.89 | MAPK14 (0.35) | GRM5MAPK14 | |
| SCHEMBL22845201 | 0.88 | S1PR2 (0.33) | GRM1PRKAA2MAPK14ALDH1A1SMN1; SMN2 | |
| SCHEMBL22845232 | 0.87 | GRM1 (0.34) | GRM5GRM1 | |
| SCHEMBL22717403 | 0.87 | AR (0.35) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL22845342 | 0.87 | MAPK14 (0.35) | GRM5GRM1MAPK14ALDH1A1SMN1; SMN2 | |
| SCHEMBL22845444 | 0.87 | MAPT (0.34) | GRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GRM5 3636/4885GRM1 4264/4885PRKAA2 2338/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | GRM5 3636/4885GRM1 4264/4885PRKAA2 2338/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | GRM5 3636/4885GRM1 4264/4885PRKAA2 2338/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GRM5 3636/4885GRM1 4264/4885PRKAA2 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.